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Introduction:  Snake venom (SV) is a rich source of proteins. Many of them are 
used for their toxicity in the treatment of diseases such as cancer. In the other hand, 
toxic agents such as immunotoxins have been investigated as a possible therapy for 
cancer in targeted therapy. They are conjugated proteins comprised of a toxin such 
as Ribosome Inactivating Proteins (RIPs) along with an antibody or cytokine that 
specifically bind to target cells. In our earlier study, we suggest using toxins derived 
from snake venom as toxic moiety in immunotoxin. 
Methods and Results: In our earlier report, we structurally compared SVPs with 
RIPs and suggested SVPs as anticancer agents in immunotoxin therapy. In this 
study, we selected LAAO, SVMP, disintegrin, PLA2, CVF and CRISP and 
compared these proteins with each other. We used UniProt and PDB database to 
discover their sequence and function data. Their structures were constructed through 
phyre2 server, then compared to other similar peptides. We demonstrated that most 
of these proteins have low molecular weight and all of them contain several 
cysteines and are able to make disulfide bonds. 
Conclusions: 
Novel therapeutics are essential to treat cancer cells. It seems that SVPs are one of 
the best candidates due to theirs toxic characteristics, some SVPs such as PLA2 and 
CRISP are smaller than others and have the most disulfide bonds.  
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